Indegene Ltd (INDGN)
₹586.80
Mkt cap
₹14,141 Cr
P/E ratio
33.20
P/B
4.22
Div yield
0.38%
ROE
14.40%
ROCE
18.80%
EPS (TTM)
₹17.67
Book value
₹139
52W range
414–627
Sector
Healthcare
Price history
Previous close
Incorporated in 1998, Indegene Ltd provides solutions consisting of analytics, technology and commercial, medical, regulatory and safety services to life science and health care organizations [1]
NSE INDGNBSE 544172
Health check
Constructive
ValuationFair
ProfitabilityAverage
GrowthHigh
TechnicalsNeutral
52-week range
−6.41% from high₹587
₹414+41.74% from low₹627
Current
₹586.80
Prev close
₹593.45
Day
−1.12%
Price performance
1D
−1.39%
1W
+2.33%
1M
−3.30%
3M
+13.70%
6M
+18.11%
1Y
+7.11%
YTD
+12.30%
Financials
Revenue, profit & margin
P/E ratio
33.2×
INDGN is 11% above the sector median of 30.0×
INDGN33.2×
Sector median30.0×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 636 | 673 | 673 | 676 | 687 | 720 | 756 | 761 | 804 | 942 | 1,003 | 1,063 | 1,122 | |
| Expenses | 515 | 524 | 534 | 548 | 561 | 589 | 608 | 606 | 664 | 783 | 840 | 889 | 937 | |
| Operating Profit | 121 | 149 | 139 | 129 | 126 | 132 | 148 | 155 | 141 | 160 | 164 | 174 | 186 | |
| OPM % | 19% | 22% | 21% | 19% | 18% | 18% | 20% | 20% | 17% | 17% | 16% | 16% | 17% | |
| Other Income | 12 | 13 | 26 | 22 | 21 | 38 | 26 | 22 | 20 | 19 | -10 | 29 | 15 | |
| Interest | 12 | 12 | 12 | 12 | 4 | 3 | 3 | 4 | 4 | 5 | 7 | 6 | 7 | |
| Depreciation | 20 | 18 | 18 | 20 | 19 | 20 | 21 | 22 | 23 | 40 | 42 | 44 | 46 | |
| Profit before tax | 101 | 132 | 134 | 120 | 124 | 146 | 149 | 152 | 133 | 135 | 105 | 153 | 147 | |
| Tax % | 25% | 25% | 29% | 27% | 26% | 25% | 21% | 23% | 23% | 24% | 24% | 24% | 24% | |
| Net Profit | 75 | 99 | 95 | 88 | 92 | 110 | 118 | 116 | 102 | 103 | 80 | 116 | 112 | |
| EPS in Rs | 3.38 | 4.45 | 4.26 | 3.67 | 3.83 | 4.58 | 4.90 | 4.85 | 4.25 | 4.28 | 3.31 | 4.82 | 4.66 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 2026FIIs12.40%2.48
DIIs15.82%7.08
Public71.76%9.58
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Syngene Intl. | ₹402.70 | 61.15 | 16,256 | 0.31% | 32 | −45.17% | 833 | −8.55% | 9.99% |
| Indegene | ₹586.80 | 33.16 | 14,141 | 0.38% | 112 | +9.99% | 1,122 | +39.55% | 18.82% |
| Suven Life Scie. | ₹258.85 | — | 7,314 | 0.00% | −128 | −147.69% | 4 | +90.91% | −79.54% |
| Vimta Labs | ₹484.90 | 26.60 | 2,168 | 0.41% | 21 | +3.46% | 112 | +9.95% | 25.23% |
| Fabtech Tech. | ₹123.90 | 18.50 | 551 | 0.48% | 15 | −67.06% | 92 | −24.19% | 13.88% |
| Novelix Pharma. | ₹68.57 | 53.93 | 195 | 0.00% | 1 | +972.73% | 37 | +65.15% | 10.87% |
| Bilcare | ₹75.33 | 8.91 | 177 | 0.00% | 15 | +473.06% | 226 | +21.20% | 7.06% |
| Median: 9 Co. | ₹123.90 | 29.95 | 551 | 0.00% | 15 | +9.99% | 92 | +30.38% | 10.87% |
Filings
Annual reports3
Concall transcripts33
PPTOct 2026RECOct 2026TranscriptAug 2026PPTAug 2026RECAug 2026PPTMay 2026TranscriptMay 2026PPTMay 2026RECMay 2026PPTApr 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025TranscriptOct 2025PPTOct 2025RECOct 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025PPTMar 2025
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 30 Oct - Indegene released audio recording of Q2 and H1 FY27 earnings call held on 30 October 2026.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 30 Oct - Audio recording of Q2 and half-year FY27 earnings call held on 30 October 2026.Announcement under Regulation 30 (LODR)-Investor Presentation 29 Oct - Analyst Presentation and Fact Sheet - financial results for the 2nd quarter and half year ended 30th September, 2026Announcement under Regulation 30 (LODR)-Press Release / Media Release 29 Oct - Indegene announced Q2 FY27 and H1 results on 29 Oct 2026; revenue rose 39.5% YoY to ₹11,223M.Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer 29 Oct - Board approved Q2 FY27 results, RSU/ESOP allotments; Company Secretary and director resigned.